LOS ANGELES--(BUSINESS WIRE)--Cougar Biotechnology, Inc., a publicly held biotechnology company, today announced that it has initiated a Phase II trial of its drug candidate CB7630 (abiraterone acetate), an orally active inhibitor of the steroidal enzyme 17alpha-hydroxylase/C17,20 lyase, for the treatment of advanced prostate cancer. The Phase II trial is being conducted at The Institute of Cancer Research, in the Cancer Research UK Centre for Cancer Therapeutics, and at The Royal Marsden NHS Foundation Trust in the United Kingdom.
